Theratechnologies Inc.

205 articles with Theratechnologies Inc.

• Theratechnologies Announces New Positive Results for two Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Ovarian Cancer

  4/27/2020

  TH1902 and TH1904 more effective and safer in vivo compared to current standard ovarian cancer treatments New data presented during the AACR Virtual Annual Meeting

• Theratechnologies to Make Oral Presentation on Oncology Platform During AACR Virtual Annual Meeting

  4/16/2020

  Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that it will make an oral presentation on new results from its sortilin targeting oncology platform during a virtual session of the annual meeting of the American Association for Cancer Research (AACR).

• Theratechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  4/16/2020

  Theratechnologies Inc., or Theratechnologies (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, announced today that Paul Lévesque, the current President and Chief Executive Officer of Theratechnologies, was granted 487,421 stock options, or Options, to purchase an aggregate of 487,421 common shares of Theratechnologies under Nasdaq Listing Rule 5635(c)(4). The grant was made outside of Theratechnologies’ existing share option p

• Theratechnologies Announces Financial Results for the First Quarter of 2020

  4/14/2020

  Theratechnologies Inc., a commercial-stage biopharmaceutical company, announced its financial results for the first quarter ended February 29, 2020.

• Theratechnologies provides business update related to current COVID-19 situation

  3/31/2020

  Theratechnologies Inc., a commercial-stage biopharmaceutical company, issued an update on the Company’s activities in relation to the current worldwide COVID-19 pandemic.

• Visceral Fat is a Predictor of Liver Fibrosis and Fibrosis Progression in People Living With HIVNew sub-analysis of MGH Study presented at CROI 2020

  3/11/2020

  Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that Dr. Lindsay Fourman, from Harvard Medical School, presented data demonstrating that visceral fat is a clinical predictor of liver fibrosis and liver fibrosis progression in an oral presentation during CROI 2020.

• Change to Theratechnologies Management

  3/2/2020

  Paul Lévesque will be appointed as President and CEO, replacing Luc Tanguay , who is retiring

• Theratechnologies Announces Financial Results for Fiscal Year 2019

  2/25/2020

  Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced its financial results for the year ended November 30, 2019.

• Theratechnologies to Announce Financial Results for Fourth Quarter and Fiscal Year 2019

  2/18/2020

  Theratechnologies Inc. (TSX: TH) (Theratechnologies) announced today that it will issue its financial results for the fourth quarter and fiscal year ended November 30, 2019, on Tuesday, February 25, 2020.

• Theratechnologies Signs Agreements With Massachusetts General Hospital and Dr. Steven Grinspoon

  2/4/2020

  Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce the signing of long-term agreements with the Massachusetts General Hospital (MGH) and Dr. Steven Grinspoon towards the development of tesamorelin for the potential treatment  of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in people living with HIV (Study)

• Theratechnologies Issues Preliminary Revenue Estimates for Fiscal Year 2019 and Revenue Guidance for Fiscal Year 2020

  12/19/2019

  Theratechnologies expects to report consolidated revenues of approximately US$63.3 million for fiscal year 2019 compared to US$45.2 million for the previous year, representing an increase of approximately 40%.

• Theratechnologies’ Oncology Platform Improves Efficacy and Tolerability of Docetaxel in Vivo and in Vitro

  12/13/2019

  Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to report on new data presented today at the San Antonio Breast Cancer Symposium (SABCS).

• Theratechnologies’ CFO to Attend Piper Jaffray 31st Annual Healthcare Conference in New York City

  11/27/2019

  Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that Philippe Dubuc, Senior Vice President and Chief Financial Officer will attend the 31st Annual Healthcare Conference starting at 12:30 p.m. on December 3rd, 2019 at the Lotte New York Palace in New York City.

• Theratechnologies Starts Commercialization of New EGRIFTA SVᵀᴹ in the United States

  11/25/2019

  Theratechnologies Inc., a commercial-stage biopharmaceutical company, is pleased to announce that EGRIFTA SVᵀᴹ is now commercially available in the United States.

• Theratechnologies’ CFO to Attend Stifel Healthcare Conference in New York City

  11/14/2019

  Theratechnologies Inc., a commercial-stage biopharmaceutical company, is pleased to announce that Philippe Dubuc, Senior Vice President and Chief Financial Officer, will attend the Stifel Healthcare Conference which will be held in New York City on November 19th, 2019.

• Trogarzo® Remains Effective Close to a Decade After Treatment Initiation

  11/7/2019

  Theratechnologies Inc., a commercial-stage biopharmaceutical company, is pleased to announce that data presented at the 17th European AIDS Conference, currently being held in Basel, Switzerland, demonstrate that Trogarzo® remains safe and effective in patients having been on treatment for almost a decade.

• Theratechnologies Provides Details About R&D Day Webcast

  10/21/2019

  Theratechnologies Inc. (“Theratechnologies” or the “Company”) (NASDAQ: THTX) (TSX: TH), a commercial-stage pharmaceutical company addressing unmet medical needs for people with orphan medical conditions, including those living with HIV, is pleased to provide details about the webcast of its R&D Day. 

• REMINDER - Tesamorelin Study Results on NAFLD Published in Lancet HIV

  10/14/2019

  NAFLD is a substantial cause of liver-related morbidity in people living with HIV and is a precursor of Non-alcoholic steatohepatitis

• Tesamorelin Study Results on NAFLD Published in Lancet HIV

  10/11/2019

  Theratechnologies Inc. is pleased to announce that results from a recent trial conducted at the Massachusetts General Hospital and the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health on the effects of tesamorelin on Non-alcoholic Fatty Liver Disease in HIV were published in the Lancet HIV.

• Canadian Commercial-Stage Biopharmaceutical Company Theratechnologies Announces NASDAQ Listing 

  10/10/2019

  Theratechnologies Inc., a commercial-stage biopharmaceutical company addressing unmet medical needs for people with orphan medical conditions, including those living with HIV, is pleased to announce that, as of today, its common shares will begin trading on the NASDAQ Capital Market under the symbol “THTX”.